Assistance publique-hôpitaux de Paris, European Georges Pompidou Hospital, Department of Biochemistry, Pharmacogenetics and Molecular Oncology, Paris Cancer Institute CARPEM, Paris, France.
Centre de Recherche des Cordeliers, INSERM, CNRS SNC 5096, Sorbonne Université, Université de Paris, Paris, France.
Br J Cancer. 2021 Nov;125(11):1544-1551. doi: 10.1038/s41416-021-01568-7. Epub 2021 Oct 12.
Patients with non-small cell lung cancer (NSCLC) receiving curative surgery have a risk of relapse, and adjuvant treatments only translate into a 5% increase in 5-year survival. We assessed the clinical significance of epithelial-mesenchymal transition (EMT) and explored its association with the [SNAIL/miR-34]:[ZEB/miR-200] regulation hub to refine prognostic information.
We validated a 7-gene EMT score using a consecutive series of 176 resected NSCLC. We quantified EMT transcription factors, microRNAs (miRs) of the miR-200, miR-34 families and miR-200 promoter hypermethylation to identify outcome predictors.
Most tumours presented with an EMT-hybrid state and the EMT score was not predictive of outcome. Individually, all miR-200 were inversely associated with the EMT score, but only chromosome-1 miRs, miR-200a, b, 429, were associated with disease-free survival (p = 0.08, 0.05 and 0.025) and overall survival (p = 0.013, 0.003 and 0.006). We validated these associations on The Cancer Genome Atlas data. Tumour unsupervised clustering based on miR expression identified two good prognostic groups, unrelated to the EMT score, suggesting that miR profiling may have an important clinical value.
miR-200 family members do not have similar predictive value. Core EMT-miR, regulators and not EMT itself, identify NSCLC patients with a low risk of relapse after surgery.
接受根治性手术的非小细胞肺癌 (NSCLC) 患者有复发的风险,辅助治疗仅将 5 年生存率提高 5%。我们评估了上皮-间充质转化 (EMT) 的临床意义,并探讨了其与 [SNAIL/miR-34]:[ZEB/miR-200] 调节枢纽的关联,以完善预后信息。
我们使用连续的 176 例 NSCLC 手术切除标本验证了一个 7 基因 EMT 评分。我们量化了 EMT 转录因子、miR-200 家族和 miR-200 启动子超甲基化的 microRNAs (miRs),以确定预后预测因子。
大多数肿瘤呈 EMT-混合状态,EMT 评分不能预测预后。单独来看,所有 miR-200 都与 EMT 评分呈负相关,但只有染色体 1 的 miR-200a、b、429 与无病生存率 (p=0.08、0.05 和 0.025) 和总生存率 (p=0.013、0.003 和 0.006) 相关。我们在 The Cancer Genome Atlas 数据上验证了这些关联。基于 miR 表达的肿瘤无监督聚类鉴定了两个预后良好的组,与 EMT 评分无关,这表明 miR 谱分析可能具有重要的临床价值。
miR-200 家族成员没有相似的预测价值。核心 EMT-miR、调节因子,而不是 EMT 本身,可识别手术后复发风险低的 NSCLC 患者。